According to the recent research report titled ‘Global Dry Eye Disease (DED) Market - Analysis By Disease (Aqueous, Evaporative, Others), Treatment, End User, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid -19 Impact, Competition and Forecast (2021-2026)’, available with Market Study Report, global dry eye disease (DED) market was worth USD 5378.59 million in 2020 and is anticipated to record a decent growth during 2021-2026.
 

Increasing proportion of working population, improved life expectancy leading to surge in elderly populace, and excessive time spent using screens are primarily stimulating global dry eye disease (DED) market growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3542234/
 

Notably, the most common reason for seeking medical eye treatment is dry eye, which affects one out of every five patients visiting optometry offices or hospital outpatient clinics.
 

Based on disease type, worldwide dry eye disease (DED) industry is split into evaporative, aqueous, and others. Of these, evaporative segment is slated to record substantial growth over the coming years, owing to latest clinical and epidemiological studies validating that most dry eye patients exhibit symptoms of aqueous deficient and mixed evaporative dry eye, with evaporative dry eye being the prominent cause.
 

With respect to treatment type, the market is divided into drugs, anti-inflammatory, eye drops, and others. As per distribution channel, the market is bifurcated into online, retailers, hospital pharmacies, and others.
 

Moving on to end user scope, global dry eye disease (DED) market is categorized into hospitals, clinics, home healthcare, and others. Among these, hospitals, followed by clinics segment, gained significant market share in the recent past, attributable to increasing number of people suffering from eye disorders, as well as manufacturers' efforts to raise public consciousness about the various types of eye disorders and their implications.
 

Elaborating on geographical spectrum, North America dry eye disease (DED) market share is expected to increase through 2026, followed by Europe and Asia Pacific. This can be ascribed to the presence of numerous leading global manufacturers in the region, with companies ramping up their manufacturing capacity in response to an increase in number of people suffering from dry eye disease as a result of excessive time spent in front of screens.
 

Major firms influencing global dry eye disease (DED) market are VISUfarma B.V., Alcon, Horus Pharma, Santen Pharmaceuticals Co. Ltd., Bausch Health Companies Inc., Johnson & Johnson, Novartis AG, Allergan plc, Novaliq GmbH, and Sentiss Pharma Pvt. Ltd.